Fabbro D - Search Results

1

Inhibition of protein kinase c-Src reduces the incidence of breast cancer metastases and increases survival in mice: implications for therapy.

Rucci N, Recchia I, Angelucci A, Alamanou M, Del Fattore A, Fortunati D, Susa M, Fabbro D, Bologna M, Teti A. Rucci N, et al. Among authors: fabbro d. J Pharmacol Exp Ther. 2006 Jul;318(1):161-72. doi: 10.1124/jpet.106.102004. Epub 2006 Apr 20. J Pharmacol Exp Ther. 2006. PMID: 16627750

2

Reduction of c-Src activity by substituted 5,7-diphenyl-pyrrolo[2,3-d]-pyrimidines induces osteoclast apoptosis in vivo and in vitro. Involvement of ERK1/2 pathway.

Recchia I, Rucci N, Funari A, Migliaccio S, Taranta A, Longo M, Kneissel M, Susa M, Fabbro D, Teti A. Recchia I, et al. Among authors: fabbro d. Bone. 2004 Jan;34(1):65-79. doi: 10.1016/j.bone.2003.06.004. Bone. 2004. PMID: 14751564

3

Pyrrolopyrimidine c-Src inhibitors reduce growth, adhesion, motility and invasion of prostate cancer cells in vitro.

Recchia I, Rucci N, Festuccia C, Bologna M, MacKay AR, Migliaccio S, Longo M, Susa M, Fabbro D, Teti A. Recchia I, et al. Among authors: fabbro d. Eur J Cancer. 2003 Sep;39(13):1927-35. doi: 10.1016/s0959-8049(03)00394-0. Eur J Cancer. 2003. PMID: 12932673

4

EGF induces biphasic S6 kinase activation: late phase is protein kinase C-dependent and contributes to mitogenicity.

Susa M, Olivier AR, Fabbro D, Thomas G. Susa M, et al. Among authors: fabbro d. Cell. 1989 Jun 2;57(5):817-24. doi: 10.1016/0092-8674(89)90796-4. Cell. 1989. PMID: 2541925

5

Protein kinases as targets for anticancer agents: from inhibitors to useful drugs.

Fabbro D, Ruetz S, Buchdunger E, Cowan-Jacob SW, Fendrich G, Liebetanz J, Mestan J, O'Reilly T, Traxler P, Chaudhuri B, Fretz H, Zimmermann J, Meyer T, Caravatti G, Furet P, Manley PW. Fabbro D, et al. Pharmacol Ther. 2002 Feb-Mar;93(2-3):79-98. doi: 10.1016/s0163-7258(02)00179-1. Pharmacol Ther. 2002. PMID: 12191602 Review.

6

Inhibitors of protein kinases: CGP 41251, a protein kinase inhibitor with potential as an anticancer agent.

Fabbro D, Buchdunger E, Wood J, Mestan J, Hofmann F, Ferrari S, Mett H, O'Reilly T, Meyer T. Fabbro D, et al. Pharmacol Ther. 1999 May-Jun;82(2-3):293-301. doi: 10.1016/s0163-7258(99)00005-4. Pharmacol Ther. 1999. PMID: 10454207 Review.

7

SRC family kinases: potential targets for the treatment of human cancer and leukemia.

Warmuth M, Damoiseaux R, Liu Y, Fabbro D, Gray N. Warmuth M, et al. Among authors: fabbro d. Curr Pharm Des. 2003;9(25):2043-59. doi: 10.2174/1381612033454126. Curr Pharm Des. 2003. PMID: 14529415 Review.

8

Targeting protein kinases in cancer therapy: a success?

Pearson MA, Fabbro D. Pearson MA, et al. Among authors: fabbro d. Expert Rev Anticancer Ther. 2004 Dec;4(6):1113-24. doi: 10.1586/14737140.4.6.1113. Expert Rev Anticancer Ther. 2004. PMID: 15606337 Review.

9

Protein tyrosine kinase inhibitors: new treatment modalities?

Fabbro D, Parkinson D, Matter A. Fabbro D, et al. Curr Opin Pharmacol. 2002 Aug;2(4):374-81. doi: 10.1016/s1471-4892(02)00179-0. Curr Opin Pharmacol. 2002. PMID: 12127869 Review.

10

Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia.

Hu Y, Liu Y, Pelletier S, Buchdunger E, Warmuth M, Fabbro D, Hallek M, Van Etten RA, Li S. Hu Y, et al. Among authors: fabbro d. Nat Genet. 2004 May;36(5):453-61. doi: 10.1038/ng1343. Epub 2004 Apr 18. Nat Genet. 2004. PMID: 15098032 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

400 results

Search Page